ROCHE REPORTS RESULTS OF ANEMIA STUDY

A A

Roche's anti-anemia agent CERA (Continuous Erythropoietin Receptor Activator) was able to control anemia in patients with chronic kidney disease (CKD) not on dialysis within a narrow target range set out in expert guidelines for more than one year, according to clinical data.

The Phase II extension data mirror those presented earlier this year in dialysis patients, suggesting that CERA provides consistent anti-anemia activity in a broad spectrum of patients with CKD. Phase II results with CERA are being confirmed in an extensive Phase III clinical program.